ATE346082T1 - Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen - Google Patents

Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen

Info

Publication number
ATE346082T1
ATE346082T1 AT03761096T AT03761096T ATE346082T1 AT E346082 T1 ATE346082 T1 AT E346082T1 AT 03761096 T AT03761096 T AT 03761096T AT 03761096 T AT03761096 T AT 03761096T AT E346082 T1 ATE346082 T1 AT E346082T1
Authority
AT
Austria
Prior art keywords
treatment
metabolic disorders
glucocorticoid receptor
receptor ligands
ligands
Prior art date
Application number
AT03761096T
Other languages
English (en)
Inventor
Geldern Thomas W Von
James T Link
Noah Tu
Philip R Kym
Chunqiu Lai
Steven J Richards
Peer B Jacobson
Richard D Bishop
Bradley D Gates
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/460,491 external-priority patent/US7141559B2/en
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of ATE346082T1 publication Critical patent/ATE346082T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03761096T 2002-06-19 2003-06-17 Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen ATE346082T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17475002A 2002-06-19 2002-06-19
US10/460,491 US7141559B2 (en) 2002-06-19 2003-06-12 Glucocorticoid receptor ligands for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
ATE346082T1 true ATE346082T1 (de) 2006-12-15

Family

ID=30002639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761096T ATE346082T1 (de) 2002-06-19 2003-06-17 Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen

Country Status (16)

Country Link
EP (1) EP1551860B1 (de)
JP (1) JP4611019B2 (de)
KR (1) KR101100826B1 (de)
CN (1) CN100348609C (de)
AR (1) AR040278A1 (de)
AT (1) ATE346082T1 (de)
AU (1) AU2003243622B9 (de)
CA (1) CA2488535C (de)
CY (1) CY1105982T1 (de)
DE (1) DE60309909T2 (de)
DK (1) DK1551860T3 (de)
ES (1) ES2278195T3 (de)
PT (1) PT1551860E (de)
TW (1) TWI285646B (de)
UY (1) UY27862A1 (de)
WO (1) WO2004000869A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0514302D0 (en) * 2005-07-12 2005-08-17 Karobio Ab Improved crystalline material
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EA025380B1 (ru) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
KR102020923B1 (ko) * 2011-09-19 2019-09-11 에테하 쭈리히 Ror 감마 모듈레이터
MX2015001500A (es) 2012-08-02 2015-04-08 Merck Sharp & Dohme Compuestos antidiabeticos triciclicos.
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2781217A1 (de) * 2013-03-18 2014-09-24 ETH Zurich ROR-Gammamodulatoren
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105693808B (zh) * 2015-11-05 2018-03-16 华润紫竹药业有限公司 一种醋酸乌立妥原料药杂质及其制备方法和作为标准品的用途
FR3055626B1 (fr) * 2016-09-08 2018-10-12 Hra Pharma Lab Procede de synthese d'un compose steroide comprenant un substituant n-methylaniline en position 11
FR3055627A1 (fr) * 2016-09-08 2018-03-09 Laboratoire Hra-Pharma Methode de preparation du compose cdb-3877
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (de) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetische spirochromanverbindungen
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
GB9907048D0 (en) * 1999-03-27 1999-05-19 Karobio Ab Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders

Also Published As

Publication number Publication date
KR101100826B1 (ko) 2012-01-02
KR20050016588A (ko) 2005-02-21
DK1551860T3 (da) 2007-04-02
CN1662549A (zh) 2005-08-31
DE60309909D1 (de) 2007-01-04
CY1105982T1 (el) 2011-04-06
EP1551860A1 (de) 2005-07-13
JP2005533807A (ja) 2005-11-10
TW200410983A (en) 2004-07-01
CN100348609C (zh) 2007-11-14
EP1551860B1 (de) 2006-11-22
AU2003243622A2 (en) 2004-01-06
AU2003243622B2 (en) 2009-05-28
PT1551860E (pt) 2007-02-28
UY27862A1 (es) 2004-04-30
JP4611019B2 (ja) 2011-01-12
ES2278195T3 (es) 2007-08-01
AU2003243622B9 (en) 2009-07-16
DE60309909T2 (de) 2007-06-21
AU2003243622A1 (en) 2004-01-06
WO2004000869A1 (en) 2003-12-31
CA2488535A1 (en) 2003-12-31
TWI285646B (en) 2007-08-21
AR040278A1 (es) 2005-03-23
CA2488535C (en) 2012-02-07

Similar Documents

Publication Publication Date Title
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602004030907D1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551860

Country of ref document: EP